CVE-2026-109558EdgeEver 1.6.0 through 1.112.0 Stored XSS via TemplatesPane Template Preview
Updated under an hour ago ()
Does this affect you?
It affects tianma-if EdgeEver. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.33%, higher than 25% of scored CVEs.
Do this next
Free account, 1 product
EdgeEver 1.6.0 through 1.112.0 contains a stored cross-site scripting vulnerability in TemplatesPane.tsx that renders template contentMarkdown with raw HTML via dangerouslySetInnerHTML without sanitization. Attackers can write templates containing HTML event handlers through an API or MCP token to run script on preview and access the privileged window.edgeeverDesktop bridge.
- CVSS
- 8.7 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:H/I:H/A:N
- Weakness (CWE)
- CWE-79
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.33% (percentile 25)
- Assigned by
- VulnCheck
- NVD analysis
- Deferred
- Record last updated
- Oct 13, 2026
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
tianma-if EdgeEver tianma_if:edgeever (from the name) | from 1.6.0 through 1.112.0 | CNA record |
References
- https://github.com/tianma-if/edgeever/issues/533issue-tracking
- https://github.com/tianma-if/edgeever/issues/546issue-tracking
- https://github.com/tianma-if/edgeever/commit/6b5027e8b4becbee0c0de7cd1a3d04af78ca87capatch
- https://github.com/tianma-if/edgeever/blob/f6ade70423ba366077653dbb8ac43a677933c776/apps/web/src/components/TemplatesPane.tsx#L150-L158technical-description
- https://github.com/tianma-if/edgeeverproduct
- https://www.vulncheck.com/advisories/edgeever-1.6.0-through-1.112.0-stored-xss-via-templatespane-template-previewthird-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.